Hematocrit: Which Tests to Order Alongside It

What Hematocrit Actually Measures

Hematocrit is the fraction of whole blood volume occupied by red blood cells, expressed as a percentage. A centrifuged tube of blood separates into three layers: plasma on top, a thin buffy coat of white cells and platelets in the middle, and the packed red cell column at the bottom. That bottom column divided by total tube length is your hematocrit. The WHO defines the reference interval as 41 to 53% for adult men and 36 to 48% for adult women.

Why Hematocrit Alone Is Never Enough

A single hematocrit value tells you the proportion of red cells but nothing about why that proportion changed. Red cell volume could be elevated because the body is making too many cells, or the plasma volume could be contracted from dehydration, shrinking the denominator. Both scenarios produce the same number on the report.

That ambiguity is why ordering hematocrit in isolation is considered incomplete practice. The 2018 Endocrine Society Clinical Practice Guideline on Testosterone Therapy explicitly states that hematocrit should always be evaluated "in the context of the full blood count."

Plasma Volume and the Pseudo-Polycythemia Problem

Dehydration, diuretic use, or prolonged vomiting can push hematocrit above 50% without any true increase in red cell mass. This is called relative or spurious erythrocytosis. Distinguishing it from absolute erythrocytosis requires concurrent plasma volume assessment or at minimum a clinical hydration history, which is why paired tests matter from the first abnormal reading.

The Core Paired Panel: Start Here

Every hematocrit result, whether high or low, should be interpreted alongside a complete blood count with differential. The CBC adds hemoglobin concentration, mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), white cell count, and platelet count. Together these transform a single percentage into a morphologic picture.

Complete Blood Count With Differential

The CBC is the mandatory first paired test. A 2023 clinical review in the Annals of Internal Medicine confirmed that CBC with differential remains the standard entry point for evaluating both erythrocytosis and anemia before any secondary workup is initiated.

Key CBC indices to read alongside hematocrit:

• MCV: Low MCV with low hematocrit points toward iron deficiency or thalassemia. High MCV points toward B12 or folate deficiency.
• RDW: Elevated RDW above 14.5% with low MCV suggests mixed nutritional deficiency.
• Hemoglobin: Hemoglobin and hematocrit track together at roughly a 3:1 ratio. A mismatch between the two may indicate lab error or sickle cell trait.
• Platelet and WBC counts: Elevations in all three cell lines (hematocrit, WBC, platelets) raise suspicion for polycythemia vera rather than isolated erythrocytosis.

Reticulocyte Count

The reticulocyte count measures immature red cells released from bone marrow and reflects production rate. Per NCBI StatPearls (2024), a corrected reticulocyte count above 2% in the setting of low hematocrit identifies a hyperproliferative anemia (hemolysis, hemorrhage), while a count below 2% points toward a hypoproliferative cause such as iron deficiency or marrow failure.

On the high-hematocrit side, a normal or low reticulocyte count in someone on testosterone therapy is reassuring but does not exclude erythrocytosis.

Iron Studies: The Most Commonly Missed Paired Test

Iron deficiency is the single most common cause of low hematocrit worldwide. The WHO estimates iron deficiency accounts for approximately 50% of all anemia cases globally. Yet ferritin is frequently omitted from the initial order set, leading to weeks of diagnostic delay.

Serum Ferritin

Ferritin below 30 ng/mL is diagnostic of iron deficiency in most guidelines, though the American Association of Clinical Endocrinology (AACE) Comprehensive Diabetes Management Algorithm and the ADA Standards of Care 2024 both acknowledge that ferritin can be falsely elevated by inflammation, masking true depletion. In patients with CRP above 5 mg/L, the ferritin threshold for diagnosing deficiency rises to 100 ng/mL.

Serum Iron, TIBC, and Transferrin Saturation

Total iron-binding capacity (TIBC) and transferrin saturation complete the picture. A transferrin saturation below 20% combined with TIBC above 400 mcg/dL confirms functional iron deficiency even when ferritin sits in the normal range. This pattern is especially common in athletes and in women of reproductive age.

When to Add Soluble Transferrin Receptor

Soluble transferrin receptor (sTfR) is elevated specifically in iron-deficient erythropoiesis and does not rise with inflammation. The sTfR-to-log-ferritin index above 1.5 differentiates true iron deficiency anemia from anemia of chronic disease with roughly 90% sensitivity per Punnonen et al., published in Blood.

Vitamin B12 and Folate: High-MCV Hematocrit Pairs

When hematocrit is low and MCV exceeds 100 fL, the workup shifts to megaloblastic causes. Stabler's review in the New England Journal of Medicine (2013) places B12 deficiency as the second most common correctable cause of anemia after iron deficiency.

Serum B12 and Methylmalonic Acid

Serum B12 below 200 pg/mL is overtly deficient. Values between 200 and 300 pg/mL occupy a gray zone where methylmalonic acid (MMA) serves as the functional confirmatory test. Elevated MMA above 0.4 micromol/L indicates intracellular B12 deficiency even when serum levels appear borderline. Per NIH Office of Dietary Supplements, metformin use reduces B12 absorption in up to 30% of long-term users, making this pairing especially relevant in patients with type 2 diabetes.

Red Cell Folate vs. Serum Folate

Serum folate reflects recent dietary intake and can normalize within 24 hours of a single leafy-green meal. Red cell folate is a more stable 120-day average and is the preferred paired test when the clinical picture suggests chronic deficiency. The CDC recommends red cell folate as the preferred analyte for population-level folate assessment.

Erythropoietin: The Critical Branch Point for High Hematocrit

Serum erythropoietin (EPO) is the single most important add-on test when hematocrit exceeds 52% in men or 48% in women. EPO level distinguishes primary erythrocytosis (low EPO, suggesting polycythemia vera or autonomous red cell production) from secondary erythrocytosis (high EPO, suggesting hypoxia, renal tumor, or exogenous androgen use).

The British Committee for Standards in Haematology guideline on investigation and management of erythrocytosis grades EPO measurement as a mandatory first-line investigation for any confirmed absolute erythrocytosis.

Low EPO: Rule Out Polycythemia Vera

Polycythemia vera (PV) is a myeloproliferative neoplasm driven by the JAK2 V617F mutation in over 95% of cases. Tefferi and Barbui's 2019 review in the American Journal of Hematology reports that JAK2 V617F testing with a sensitivity of greater than 99% for PV should be ordered the same day as EPO when EPO comes back suppressed. Untreated PV carries a median survival of 1.5 years without cytoreduction, which underscores the urgency of the paired panel.

High EPO: Secondary Erythrocytosis Workup

High EPO with high hematocrit points toward tissue hypoxia or an EPO-secreting lesion. The paired workup includes:

• Overnight pulse oximetry or polysomnography (sleep apnea is the most common acquired cause)
• Arterial blood gas to assess oxygen saturation at rest
• Renal ultrasound or CT to exclude renal cell carcinoma or hepatocellular carcinoma, both known EPO producers
• Hemoglobin oxygen dissociation curve or high-affinity hemoglobin gene panel if no structural cause is found

Testosterone Therapy and Hematocrit: A High-Stakes Pairing

Exogenous testosterone is the most common iatrogenic cause of erythrocytosis in men under 60. Testosterone stimulates EPO production and directly suppresses hepcidin, increasing intestinal iron absorption and red cell synthesis. The 2018 Endocrine Society Testosterone Therapy guideline sets a hard threshold: if hematocrit exceeds 54%, testosterone should be withheld until levels fall below 50%.

Incidence Figures From Clinical Trials

The TRAVERSE trial (N=5,246), reported in the New England Journal of Medicine in 2023, found that testosterone replacement in men with hypogonadism produced hematocrit above 54% in 5.5% of participants vs. 0.8% in the placebo group over a mean follow-up of 33 months. That is a roughly 7-fold elevation in erythrocytosis risk.

Mandatory Paired Labs for Men on TRT

The following panel should run at baseline, then at 3 months, and every 6 months thereafter per Endocrine Society 2018 recommendations:

| Test | Timing | Threshold Action | |---|---|---| | Hematocrit | Baseline, 3 mo, 6 mo | Hold TRT if >54% | | Hemoglobin | Same draw | Evaluate if >18.5 g/dL | | Serum EPO | If hematocrit >52% | Low EPO: order JAK2 | | Total testosterone (trough) | Same draw | Target 400 to 700 ng/dL | | SHBG | Baseline, 6 mo | Guides free T calculation | | PSA | Baseline, 3 mo, annually | Hold if rise >1.4 ng/mL in 12 mo | | Lipid panel | Baseline, annually | Monitor HDL suppression | | Ferritin | If hematocrit <40% | Iron repletion before dose increase |

Dose Adjustment vs. Phlebotomy

When hematocrit rises above 54% on TRT, the two main interventions are dose reduction and therapeutic phlebotomy. The American Urological Association 2018 testosterone deficiency guideline notes that phlebotomy rapidly reduces hematocrit but can deplete iron stores, paradoxically stimulating EPO and driving further red cell production. Dose reduction is therefore preferred as the primary step when the patient is otherwise asymptomatic.

How to Raise a Low Hematocrit: Paired Tests Guide Treatment

Treatment of low hematocrit depends entirely on the underlying cause identified through paired testing.

Iron Deficiency Confirmed by Ferritin <30 ng/mL

Oral ferrous sulfate 325 mg three times daily (delivering approximately 195 mg elemental iron daily) raises hematocrit by roughly 1 percentage point per week in iron-deficiency anemia. Tolkien et al., BMJ Open 2015, demonstrated that twice-daily dosing produces equivalent absorption to three-times-daily with 40% fewer gastrointestinal adverse events. Recheck CBC and ferritin at 4 weeks.

Intravenous iron (ferric carboxymaltose 750 to 1,500 mg in a single infusion) is preferred when oral tolerance is poor or absorption is impaired by celiac disease, gastric bypass, or inflammatory bowel disease. Evstatiev et al., Gastroenterology 2011 showed hematocrit normalization at 8 weeks in 65% of IBD patients using IV iron vs. 35% with oral iron.

B12 or Folate Deficiency

Cyanocobalamin 1,000 mcg intramuscular weekly for 4 weeks, then monthly, is the standard repletion protocol for B12 deficiency with neurologic features. Oral high-dose B12 (1,000 to 2,000 mcg daily) achieves equivalent serum levels through passive absorption in patients without neurologic involvement, per Butler et al., Cochrane Database 2006. Reticulocyte count rises within 3 to 5 days of starting B12 and peaks at day 7, serving as an early treatment-response marker.

Anemia of Chronic Disease

Anemia of chronic disease (ACD) produces low hematocrit with normal or elevated ferritin, normal MCV, and low transferrin saturation. The treatment target is the underlying inflammatory condition. Weiss and Goodnough's landmark review in the New England Journal of Medicine (2005) established that EPO-stimulating agents are indicated in ACD only when hemoglobin falls below 10 g/dL and the underlying disease is not controllable, such as in myelosuppressive chemotherapy.

How to Lower a High Hematocrit: Paired Tests Guide Intervention

A hematocrit above 52% in the absence of dehydration requires the full secondary panel described above before any intervention.

Hydration Status Assessment

Check serum sodium, BUN, and creatinine alongside hematocrit when the patient reports recent poor fluid intake, heavy sweat loss, or diuretic use. BUN-to-creatinine ratio above 20 suggests prerenal dehydration. Correcting volume status alone may normalize hematocrit within 24 to 48 hours without any further treatment.

Phlebotomy Protocol

For confirmed absolute erythrocytosis with hematocrit above 54%, phlebotomy of 450 to 500 mL per session lowers hematocrit by approximately 3 percentage points. The European LeukemiaNet 2018 PV guidelines recommend a target hematocrit below 45% for all PV patients, based on the CYTO-PV trial (N=365), which showed a 3-fold reduction in cardiovascular events at that threshold vs. A target of 45 to 50%.

Low-dose aspirin 81 mg daily is added to phlebotomy in PV patients because the thrombotic risk from hyperviscosity compounds with platelet activation. Hydroxyurea is reserved for high-risk PV (age above 60 or prior thrombotic event) at a starting dose of 500 mg twice daily.

Normal Hematocrit Range: Age, Sex, and Altitude Adjustments

Standard reference intervals do not apply uniformly across all populations.

Sex-Specific Ranges

The difference between male and female reference ranges (approximately 5 percentage points) is driven by testosterone's erythropoietic effect and by monthly menstrual blood loss in premenopausal women. Per the WHO hemoglobin thresholds document, anemia is defined as hemoglobin below 13.0 g/dL in men (corresponding to hematocrit approximately 39%) and below 12.0 g/dL in non-pregnant women (hematocrit approximately 36%).

Altitude Corrections

At elevations above 1,500 meters, the body compensates for lower oxygen partial pressure by increasing EPO and red cell mass. Residents of Denver (1,609 m) have mean hematocrit approximately 2 percentage points higher than sea-level populations. The CDC NHANES III correction factor adjusts hemoglobin thresholds upward by approximately 0.2 g/dL per 500 m above 1,000 m.

Pediatric and Geriatric Ranges

Neonates have hematocrit as high as 60 to 65% due to fetal hemoglobin and polycythemia of birth. Values normalize to adult ranges by age 12 months. In adults over 65, hematocrit commonly falls to the 38 to 42% range due to declining EPO response and lower androgen levels. Guralnik et al., Blood 2004 found that hematocrit below 39% in community-dwelling older adults was independently associated with a 1.6-fold increase in all-cause mortality over 4 years.